Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
Sign Up to like & getrecommendations! Published in 2021 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13219
Abstract: In post‐menopausal women, incidence of heart failure with preserved ejection fraction is higher than in men. Hormonal replacement therapies did not demonstrate benefits. We tested whether the non‐steroidal mineralocorticoid receptor antagonist finerenone limits the progression… read more here.
Keywords: heart; receptor blockade; heart failure; mineralocorticoid receptor ... See more keywords
Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials
Sign Up to like & getrecommendations! Published in 2019 at "Heart Failure Reviews"
DOI: 10.1007/s10741-019-09790-5
Abstract: The efficacy and safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure (HF) are controversial. To explore the role of MRAs in HF patients with an ejection fraction of no more than 45%,… read more here.
Keywords: sucra; efficacy safety; heart failure; finerenone ... See more keywords
Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone
Sign Up to like & getrecommendations! Published in 2020 at "Current Cardiology Reports"
DOI: 10.1007/s11886-020-01399-7
Abstract: We aim to review the mechanism of action and safety profile of mineralocorticoid receptor antagonists (MRAs) and discuss the differences between selective and non-selective MRAs. More specifically, finerenone is a new medication that is currently… read more here.
Keywords: mineralocorticoid receptor; review; finerenone; receptor ... See more keywords
Finerenone: First Approval
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-021-01599-7
Abstract: Finerenone (Kerendia®), a first-in-class, orally administered, selective, nonsteroidal mineralocorticoid receptor antagonist (MRA), is being developed by Bayer HealthCare Pharmaceuticals for the treatment of diabetic kidney disease (DKD) and heart failure (HF), including chronic HF (CHF).… read more here.
Keywords: first approval; disease; finerenone; finerenone first ... See more keywords
The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical science"
DOI: 10.1042/cs20220212
Abstract: Despite strong preclinical data supporting the use of mineralocorticoid receptor antagonists (MRAs) to provide cardiorenal protection in rodent models of diabetes, the clinical evidence of their utility in treating chronic kidney disease (CKD) has been… read more here.
Keywords: kidney; chronic kidney; finerenone; type diabetes ... See more keywords
Cardiorenal benefits of finerenone: protecting kidney and heart
Sign Up to like & getrecommendations! Published in 2023 at "Annals of Medicine"
DOI: 10.1080/07853890.2023.2171110
Abstract: Abstract Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors. Overactivation of mineralocorticoid receptors… read more here.
Keywords: disease; kidney; progression; finerenone ... See more keywords
Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2022.2130889
Abstract: ABSTRACT Introduction Diabetic kidney disease (DKD) represents a leading cause of morbidity and mortality in subjects with diabetes and develops in more than one third of diabetic patients. Steroidal mineralocorticoid receptor antagonists (MRAs – eplerenone… read more here.
Keywords: safety; diabetic kidney; kidney disease; finerenone ... See more keywords
Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2022.2094770
Abstract: ABSTRACT Introduction Approximately 40% of people with type 2 diabetes (T2D) also have chronic kidney disease (CKD), which substantially increases their risk of cardiovascular (CV)-related complications and mortality. Until recently, no approved therapies have directly… read more here.
Keywords: disease; kidney; chronic kidney; finerenone ... See more keywords
The non-steroidal MRA finerenone in cardiorenal medicine: a state-of-the-art review of the literature.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of hypertension"
DOI: 10.1093/ajh/hpac124
Abstract: Steroidal mineralocorticoid-receptor-antagonists (MRAs), such as spironolactone and eplerenone, are guideline-directed therapies in patients with heart failure with reduced ejection fraction or resistant hypertension. However, the associated risk of hyperkalemia and hormonal side effects limit their… read more here.
Keywords: steroidal mra; finerenone; risk; non steroidal ... See more keywords
Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage
Sign Up to like & getrecommendations! Published in 2021 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehab724.2284
Abstract: The nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone and SGLT2 inhibitors have demonstrated clinical benefits in HFrEF and CKD patients with T2D. Cardiovascular protection with finerenone and the SGLT2 inhibitor empagliflozin in combination in hypertensive cardiorenal… read more here.
Keywords: combination; cardiovascular protection; finerenone sglt2; finerenone ... See more keywords
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study
Sign Up to like & getrecommendations! Published in 2022 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfac157
Abstract: ABSTRACT Background In FIGARO-DKD, finerenone reduced the risk of cardiovascular events in patients with type 2 diabetes (T2D) and stage 1–4 chronic kidney disease (CKD). In FIDELIO-DKD, finerenone improved kidney and cardiovascular outcomes in patients… read more here.
Keywords: figaro dkd; kidney; kidney outcomes; finerenone ... See more keywords